Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika Virus Through Direct Inactivation and Interferon Pathway

Products Related to Zika, WestNile, Dengue, Malaria, T.B, Chikungunya, HIV, SARS

Product# 10003-10: Recombinant Zika NS1 Protein (E.coli)

Product# 10003: Recombinant Zika NS1 Protein (E.coli)

Product#  10001: Recombinant Zika Envelope Protein (E.coli)

 

 

Abstract

 

Figure 1

Sequence relationships of the nine peptides. Sequence relationships of the nine antimicrobial peptides (AMPs). Amino-acid sequences of the AMPs were compared with the Vector NTI software suite (Thermo Fisher Scientific). (A) Working relationships between the nine AMPs derived from human and bovine cathelicidins are shown in the dendrogram based on the amino-acid sequence homology. The length of each tree branch is proportional to the number of amino-acid differences between a particular sequence and its theoretical ancestral sequence (presented as parentheses for each sequence). (B) Amino-acid sequence alignment. Color codes indicate degree of similarity: yellow, font red: identical; cyan, font blue: conservative; green, font black: similar; no color, font green: weakly similar, no color, font black: non-similar.

Cell Viability Assay

Cell viability was examined by the CellTiter 96 ^®Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA). Vero cells and astrocytes were seeded into 96-well tissue culture plates (Fisher Scientific) and treated with fresh growth medium containing different concentrations of each peptide for 2 or 4 days at 37°C. At the experimental end point, MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] was added to the cultures and incubated for 1 h. The absorbance at 490 nm was recorded through BioTek Gen5 data analysis software (Winooski), VT, optical density (OD) values were used as a representation of cell viability.

ZIKV Plaque-Forming Assay

Vero cells were plated into 12-well plates at 5 (105 cells/well the day before infection). On the day of infection, the monolayers of Vero cells were inoculated with 100 µL of 10-fold serial dilutions of viral stocks and incubated at 37oC for 1 h. After viral inoculation, medium containing ZIKV particles was removed and 1 ml overlay containing 0.6% molecular biology grade agarose (Agarose Unlimited, Alachua, FL, USA) in Modified Eagle Medium (Gibco) with 2% FBS. Cells were maintained at 37°C in 5% CO₂ for 4 days. On day 5, cells were fixed with 4% paraformaldehyde solution in PBS and stained with 1% crystal violet solution in 20% methanol in water. Viral plaques were photographed using a CanonScan 9950F scanner and each plaque was counted as a plaque-forming unit (PFU). Viral titer was calculated as PFU/[volume virus (mL) × (dilution factor)].

Real-Time RT-PCR

Total mRNA was isolated with TRIzol Reagent (Thermo Fisher Scientific) and RNeasy Mini Kit (QIAGEN Inc., Valencia, CA, USA) following the manufacturer’s recommendations. Two real-time RT-PCR methods were used for the current studies. First, SYBR Green-based RT-PCR assay was used to determine intracellular ZIKV RNA in Vero cells. For this assay, reverse transcription was performed using Verso cDNA synthesis Kit (Thermo Fisher Scientific) and 1 µg of total RNA in a 15-µL final volume. The RT-PCR analyses were performed using 7.5-µL SYBR Green PCR Master Mix (Thermo Fisher Scientific) with 0.5-µL cDNA, 1.5-µL H₂O, 5.5-µL oligonucleotide primer pairs at 10 µM. Primers used were ZIKV RNA: forward sequence 5-TGGGAGGTTTGAAGAGGCTG-3, reverse sequence 5-TCTCAACATGGCAGCAAGATCT-3; GAPDH: forward sequence 5-GGAGCGAGATCCCTCCAAAAT-3, reverse sequence 5-GGCTGT TGTCATACTTCTCAT GG-3. PCR program: 1, 50°C for 2 min; 2, 95°C for 2 min; 3, 95°C for 15 s; 4, specific annealing temperature for 15 s; 5, 72°C for 1 min. Steps 2–4 were repeated 40 times. All samples were amplified in triplicate for analysis. Relative ZIKV RNA levels were determined and standardized with a GAPDH internal control using comparative ΔΔCT method (35). Second, TaqMan-based RT-PCR assay was used to determine intracellular ZIKV RNA and other gene expressions in Figures ​Figures33–6 and extracellular ZIKV RNA in Figure ​Figure3.3. The TaqMan assay was performed in a StepOne^TM Real-Time PCR system (Thermo Fisher Scientific). Primers used for TaqMan real-time RT-PCR were all from the Thermo Fisher Scientific, which included ZIKV (forward sequence: 5-TTGGTCATGATACTGCTGATTGC-3, reverse sequence: 5- CCTTCCACAAAGTCCCTATTGC-3, and probe sequence: 5′-CGGCATACAGCATCAGGTGCATAGGAG-3), IFN-α2 (Hs00265051_s1), IFN-β1 (Hs01077958_s1), eukaryotic 18-s rRNA (Hs99999901_s1), β-actin (Hs99999903_m1), and GAPDH (Catalog number: 4310884E). Relative ZIKV mRNA levels were determined and standardized with a GAPDH or 18-s rRNA endogenous control using comparative ΔΔCT method (35). All reference genes, including GAPDH, β-actin, and 18-s rRNA, detected identical changes of genes (Figure S1 in Supplementary Material). Therefore, typically one was chosen as the endogenous control for gene expressions in the current studies. For ZIKV in supernatants, RNA was extracted from the supernatants through TRIzol™ LS Reagent (Thermo Fisher Scientific, 10296028) following the manufacturer’s manual. Since reference genes were not expressed in the supernatant RNA, an equal volume of extracted RNA was used in real-time RT-PCR. Quantitative genomic RNA from ZIKV (NR-1838DQ, ATCC) was used as a standard to calculate viral copies. All primers used in the study were tested for amplification efficiencies and the results were similar to each other.

 

 

 

Figure 3

Antimicrobial peptides derived from cathelicidins inhibit Zika virus (ZIKV) infection in human fetal astrocytes. (A) Human fetal astrocytes were treated with doses of the selected peptides ranging from 1 to 50 µM. After 24 h, the cultures were washed and treated with same doses of peptides in fresh medium for another 24 h. Cell viability was determined by a colorimetric MTS assay. Results shown are the averages ±SD of experiments performed in triplicate. Data were analyzed by nonlinear regression and assessed the EC50 for each of the antimicrobial peptides. (B–E) Astrocytes were treated with doses of antimicrobial peptides ranging from 0.4 to 10 µM for 2 h then infected with ZIKV at the MOI of 0.5. After 24 h, the cultures were washed and treated with same doses of antimicrobial peptides in fresh medium for another 24 h. At the experimental endpoint, intracellular ZIKV RNA (B) was determined through real-time RT-PCR in total cellular RNA. Data were normalized to GAPDH and presented as fold change (in log scale) compared with ZIKV group. Extracellular ZIKV RNA [(C), in log scale] was determined through real-time RT-PCR using total RNA isolated from cell-free supernatants. ZIKV virion levels (in log scale) were determined by adding cell-free culture supernatants to Vero cells and overlaid with Agar gel in viral PFA (D). Viral plaques were manually counted and calculated as PFU/mL (E). * p < 0.05, ** p < 0.01, and *** p < 0.001, as compared with the ZIKV group without peptide treatment (ANOVA, N = 3).

 

Figure 6

Antimicrobial peptides (AMPs) are negatively correlated with IFN-α2 expression in ZIKV-infected astrocytes. (A–D) Astrocytes were infected with Zika virus (ZIKV) at the MOI of 0.5 and treated with doses of AMPs ranging from 0.4 to 10 µM. After 24 h, the cultures were washed and treated with same doses of AMPs in fresh medium for another 24 h. RNA was isolated from cells and the expression of IFN-α2 (A) and IFN-β1 (C) was determined through real-time RT-PCR. Data were normalized to 18-s rRNA and presented as fold change compared with ZIKV group. Correlation of the IFN-α2 (B) and IFN-β1 (D) with ZIKV infection levels was determined by Spearman correlation. *** p < 0.001, as compared with the uninfected control group. ^# p < 0.05, ^## p < 0.01, ^### p < 0.001, as compared with the ZIKV group (ANOVA, N = 3). (E,F) Human astrocytes were pretreated with anti-IFN-α neutralizing antibodies (E) or 1-µM fludarabine (F) for 2 h, then treated with AMPs for 2 h before ZIKV infection at the MOI of 0.5. Rabbit IgG and DMSO were used as control for anti-IFN-α neutralizing antibodies and fludarabine, respectively. At 24 h after infection, total RNA was collected and ZIKA RNA was detected through real-time RT-PCR. Recombinant IFN-α2 was tested for ZIKV inhibition at 1000 units/mL. Data were normalized to 18-s rRNA and presented as fold change in log scale compared with ZIKV group. CTL, control. *** p < 0.001, compared with the corresponding ZIKV group treated with control IgG or DMSO; ^# p < 0.05, ^### p < 0.001, compared with the ZIKV group treated with the same AMP (ANOVA, N = 3).

Viral Attachment Assay

Viral attachment assay was adapted from a previous publication (36) with modifications. Briefly, primary human fetal astrocytes were pre-incubated at 4°C for half an hour and then treated with AMPs along with ZIKV infection at the MOI of 0.5. After infection at 4°C for 2 h, cultures were washed with fresh medium for three times and RNA was isolated from whole cells. ZIKV RNA was determined through real-time RT-PCR. Data were normalized to 18-s rRNA and presented as fold change compared with the ZIKV group. One experimental group was subjected to trypsin digestion to remove any attached virions. This group served as a positive control for the viral attachment experiment.

Direct Inactivation of ZIKV by AMPs

Zika virus viral stocks were diluted to 10⁶ PFU/mL with serum-free medium and peptides were added at the indicated final concentrations. The mixtures were incubated at 37°C for 1–4 h. At each time point, 200 µL of the mixtures was removed for virus yield determination. Ten-fold serial dilutions of the mixtures were prepared and number of infectious Zika virions in the inoculum was determined by the aforementioned plaque-forming assay on Vero cell monolayers.

Statistical Analysis

Statistical analyses were performed using GraphPad Prism 7.00 and IBM SPSS Statistics Version 22. The data were presented as means ± SD unless specified otherwise. The EC₅₀ values of cytotoxicity data were calculated using GraphPad Prism 7.00. Differences between groups were compared using the one-way ANOVA with Bonferroni post-test for multiple comparison. For the data that are not normally distributed due to varying levels of ZIKV inhibition, we applied the log transformation to meet normality of data distribution before statistical tests. p < 0.05 was considered as significant. All assays were performed at least three times in triplicate or quadruplicate.

Go to:

Results

AMPs Inhibit ZIKV Infection in Vero Cells

To determine whether AMPs have anti-ZIKV effects in vitro, we selected nine peptides, including eight active AMPs and one non-antimicrobial control peptide––RI10. Most of these peptides are closely related to human cathelicidin LL-37. LL-37 is aligned with GI-20 (32), GF-17 (28), and RI-10 (29), which corresponds to residues 13–32, 17–32, and 19–28 of LL-37, respectively, while another two peptides, 17BIPHE2 and merecidin, are designed based on GF-17 to gain stability to proteases such as chymotrypsin (Figures ​(Figures1A,B).1A,B). In contrast, bovine cathelicidin-derived BMAP-18 and database-obtained DASamP2 are more distantly related to LL-37 compared with those aforementioned AMPs (30, 32). BMAP-18 and GF-17 share a similar amphipathic helical pattern, where four residues are identical and seven residues are semi-conserved (Figure ​(Figure1).1). We first evaluated the cytotoxicity of Vero cells after treatment of AMPs through a cell viability MTS assay. Vero cells were exposed to each of the nine peptides with doses ranging from 0 to 50 µM for 48 h. Among the AMPs, five showed cell viability of more than 50% compared with untreated controls (peptide concentrations at 0 µM) at the highest dose tested (EC₅₀ > 50 µM). These five AMPs include RI-10, DASamP2, GF-17, BMAP-18, and GI-20 (Figure ​(Figure2A).2A). In contrast, LL-37, GI-20D-form, 17BPIHE2, and merecidin exhibited varying levels of cytotoxic effects with EC₅₀ ranging from 4 to 20 µM. To test the anti-ZIKV effects of the AMPs, we chose the doses of 0.4, 2, and 10 µM on the basis of cytotoxicity and early work that showed their effective treatment concentrations (32). ZIKV infection was tested at 48-h post-infection because our earlier work showed that infection causes significant cytotoxicity beyond this time point (27). All AMPs except RI-10 showed dose-dependent decrease of ZIKV RNA compared with untreated controls (Figure ​(Figure2B).2B). Specifically, Merecidin, LL-37, GI-20, and GI-20 D-form significantly decreased ZIKV RNA at 0.4 µM. DASamP2, GF-17, LL-37, BMAP-18, GI-20, and GI-20 D-form significantly decreased ZIKV RNA at 2 µM. All peptides except RI-10 significantly decreased ZIKV RNA at 10 µM. Taken together, these data demonstrate that eight out of the nine selected AMPs inhibit ZIKV infection in Vero cells.

 

 

Figure 2

Antimicrobial peptides derived from cathelicidins inhibit Zika virus (ZIKV) infection in Vero cells. (A) Vero cells were treated with doses of peptides ranging from 1 to 50 µM. After 24 h, the cultures were washed and treated with same doses of peptides in fresh medium for another 24 h. Cell viability was determined by a colorimetric MTS assay. Results shown are the averages ±SD of experiments performed in triplicate. Data were analyzed by non-linear regression. The EC50 was assessed for each of the antimicrobial peptides. (B) Vero cells were treated with doses of peptides ranging from 0.4 to 10 µM for 2 h then infected with ZIKV at the MOI of 0.5. After 24 h, the cultures were washed and treated with same doses of peptides in fresh medium for another 24 h. ZIKA RNA was detected in total cellular RNA through real-time RT-PCR. Data were normalized to GAPDH and presented as fold change (in log scale) compared with ZIKV group. ** p < 0.01 and *** p < 0.001, as compared with the ZIKV group without the peptide treatment (ANOVA, N = 3).

Cathelicidin-Derived AMPs Inhibiting ZIKV Infection in Primary Human Fetal Astrocytes

Since significant cytotoxicity could interfere with the interpretation of the anti-ZIKV activity by AMPs. We treated Vero cells for 2 days (Figure S2A in Supplementary Material) and 4 days (Figure S2B in Supplementary Material) with the 9 AMPs at 10 µM and evaluated the cytotoxicity through the MTS assay. Consistent with Figure ​Figure2A,2A, GF-17, RI-10, and BMAP-18 caused minimal cytotoxicity to the Vero cells. Based on these cytotoxicity data, we excluded 17BIPHE2, Merecidin, LL-37, GI-20, and GI-20D-form from further testing. GF-17 and BMAP-18 both belong to the family of cathelicidin. Therefore, we decided to investigate how cathelicidin-derived GF-17 and BMAP-18 impact ZIKV infection. The inactive peptide RI-10 was included as a negative control. Since human fetal astrocytes are a natural host of ZIKV, we tested the effects of GF-17 and BMAP-18 treatment in this cell host. Cytotoxic effects of BMAP-18, GF-17, and RI-10 on human astrocytes were evaluated and no obvious cytotoxicity was observed over 2 days (EC₅₀ > 50 µM, Figure ​Figure3A;3A; Figure S3A in Supplementary Material) and 4 days (Figure S3B in Supplementary Material) of exposure to them. Therefore, consistent with the data in Vero cells, BMAP-18, GF-17, and RI-10 are not cytotoxic to human fetal astrocytes.

Next, we tested antiviral effects of RI-10, BMAP-18, and GF-17 in ZIKV-infected human fetal astrocytes that we previously characterized (27). Pre-treatments with GF-17 and BMAP-18, but not RI-10, decreased intracellular ZIKV RNA in a dose-dependent manner (Figure ​(Figure3B).3B). Both GF-17 and BMAP-18 showed most significant inhibitory effect (p < 0.001) at the concentration of 10 µM. At 2 µM, GF-17 and BMAP-18 reduced intracellular ZIKV RNA to 46 and 15% of the untreated ZIKV group, respectively. At 10 µM, GF-17 and BMAP-18 reduced intracellular ZIKV RNA to 1 and 4% of the untreated ZIKV group, respectively. The inhibitory effects of GF-17 and BMAP-18 were also demonstrated on extracellular ZIKV RNA in the culture supernatants. For BMAP-18, the level of ZIKV RNA was reduced to 5.6% at 2 µM (p < 0.01) and 1.3% at 10 µM (p < 0.01). For GF-17, the ZIKV yield was reduced to 16.7% at 2 µM (p < 0.05) and 0.1% at 10 µM (p < 0.01) (Figure ​(Figure3C).3C). Consistent with the ZIKV RNA data, ZIKV virions were reduced by GF-17 and BMAP-18, but not RI-10, in a dose-dependent manner (Figures ​(Figures3D,E).3D,E). Taken together, these data demonstrate that GF-17 and BMAP-18 inhibit ZIKV infection in primary human fetal astrocytes.

To test the therapeutic potential of cathelicidin-derived AMPs against ZIKV, we changed the treatment of AMPs from pre-infection treatment to 24-h post-infection treatment. ZIKV RNA was determined at 24 h after AMP treatment (Figure ​(Figure4A).4A). Post-ZIKV treatment with GF-17 for 24 h significantly decreased ZIKV RNA compared with the untreated ZIKV group [p < 0.001; Figure ​Figure4B)].4B)]. ZIKV RNA in BMAP-18-treated group also trended downward; however, the difference was not significant (p = 0.063). Also, at 24 h after AMP treatment, Zika virions were quantified through plaque-forming assay; fewer virions were found in BMAP-18- and GF-17-treated groups, compared with those of untreated ZIKV group (Figures ​(Figures4C,D),4C,D), suggesting that similar to pre-infection treatment, post-infection treatment with BMAP-18 or GF-17 also inhibits ZIKV infection.

 

 

Figure 4

Antimicrobial peptides treatment post-infection is still effective in inhibiting Zika virus (ZIKV) infection. (A) Primary human fetal astrocytes were infected with ZIKV at the MOI of 0.5 for 24 h before antimicrobial peptide treatment at 10 µM. (B–D) At 24-h post-antimicrobial peptide treatment, RNA was isolated from cells and ZIKV RNA was determined through real-time RT-PCR. Data were normalized to GAPDH and presented as fold change compared with ZIKV group (B). Cell-free supernatants were collected and subjected to PFA for determination of viral titer (C,D). CTL, control. * p < 0.05, ** p < 0.01, and *** p < 0.001 as compared with the ZIKV group without peptide treatment (ANOVA, N = 4).

AMPs Inhibiting ZIKV at 2-h Post-Infection

To determine the mechanism(s) of AMP-mediated ZIKV inhibition, we first investigated the ZIKV attachment and viral entry. For viral attachment assay, astrocytes were cultured at 4°C for half an hour before the addition of ZIKV and peptides, and the total RNA was harvested after 2 h at 4°C. An extra group of astrocytes was trypsinized to remove any attached virions. This group serves as a positive control for the assay. BMAP-18, GF-17, and RI-10 treatment did not alter the ZIKV RNA levels in astrocytes at 4°C (Figure ​(Figure5A),5A), suggesting that these AMPs do not affect ZIKV attachment. To determine whether AMPs affect ZIKV entry to the astrocytes, we treated astrocytes with AMPs for 2 h at 37°C before ZIKV infection and collected total RNA at 2-h post-infection (Figure ​(Figure5B).5B). GF-17 and BMAP-18, but not RI-10, significantly decreased ZIKV RNA (p < 0.01, Figure ​Figure5B)5B) compared with those of untreated ZIKV group. Taken together, these data indicate that, although GF-17 and BMAP-18 do not affect viral attachment, they impact ZIKV entry at 2-h post-infection.

 

 

Figure 5

Antimicrobial peptides do not affect Zika virus (ZIKV) viral attachment but inhibit early ZIKV infection. (A) Primary human fetal astrocytes were pre-incubated at 4°C for half an hour and then treated with antimicrobial peptides along with ZIKV infection at the MOI of 0.5 for 2 h. Cultures were then washed with fresh medium for three times. ZIKV RNA was determined through real-time RT-PCR in total cellular RNA. Data were normalized to 18-s rRNA and presented as fold change compared with the ZIKV group. The trypsin digestion group readily removes any attached virions and thus serves as positive control. (B) Primary human fetal astrocytes treated with antimicrobial peptides for 2 h at 37°C then infected with ZIKV at the MOI of 0.5. After infection for 2 h, cultures were washed with fresh medium for three times and RNA was isolated from whole cells. ZIKV RNA was determined through real-time RT-PCR. Data were normalized to 18-s rRNA and presented as fold change compared with ZIKV group. * p < 0.05 and *** p < 0.001, as compared with the ZIKV group without peptide treatment (ANOVA, N = 3).

Interferon Signaling Is Associated With ZIKV Infection and AMP Effects

To further explore the mechanism of AMP-mediated ZIKV inhibition, the levels of IFN-α2 and IFN-β1 during individual AMP treatment with or without ZIKV infection, were determined through real-time RT-PCR (Figures ​(Figures6A–D).6A–D). In uninfected fetal astrocytes, control peptide RI-10 did not affect the expression levels of IFN-α2 (Figure ​(Figure6A).6A). In contrast, GF-17 treatment significantly increased IFN-α2 expression (p < 0.0001). Similarly, BMAP-18 also increased IFN-α2 by 7 folds though the difference was not statistically significant (Figure ​(Figure6A).6A). In ZIKV-infected fetal astrocytes, both GF-17 and BMAP-18, but not RI-10, significantly increased IFN-α2 expression levels in a dose-dependent manner (Figure ​(Figure6A).6A). Furthermore, the level of IFN-α2 is negatively correlated with ZIKV RNA level in infected cells (Figure ​(Figure6B).6B). Together, these data suggest that AMPs induce the IFN-α2 expression in fetal astrocytes and the AMP-induction of IFN-α2 likely has a negative impact on ZIKV infection in the cultures. The analysis of IFN-β1 reveals that in uninfected fetal astrocytes, AMP treatment did not affect IFN-1 expression levels. Surprisingly, in ZIKV-infected fetal astrocytes, AMP treatment significantly decreased IFN-β1 expression levels (Figure ​(Figure6C)6C) and the levels of IFN-β1 were positively correlated with ZIKV RNA level (p < 0.01) (Figure ​(Figure6D).6D). Therefore, these data suggest that IFN-β1 is likely more of a reflection on the ZIKV infection levels and does not play a role in AMP-mediated ZIKV inhibition.

To determine the role of IFNs during AMP-mediated ZIKV inhibition, we first treated astrocytes with recombinant human IFN-α before ZIKV infection. As expected, IFN-α treatment significantly inhibited ZIKV infection (Figure ​(Figure6E).6E). Next, we used a neutralizing antibody for IFN-α and a small molecule fludarabine known to be an inhibitor for IFN signaling (37). The neutralizing antibody for IFN-α neutralizes multiple subtypes of human IFN-α, including IFN-α2, IFN-α8, and IFN-α21. Inhibition of type-I IFN signaling through neutralizing IFN-α antibody (Figure ​(Figure6E)6E) or fludarabine (Figure ​(Figure6F)6F) dampened but did not completely block the GF-17- and BMAP-18-mediated ZIKV inhibition, suggesting that GF-17- and BMAP-18-induced IFN signaling is limiting ZIKV infection in the fetal astrocytes. The modest effect of neutralizing IFN-α antibody also indicates that type-I IFN-independent ZIKV inhibition pathway exists.

GF-17 Directly Inactivating Zika Viral Particles

To determine whether GF-17 and BMAP-18 have a direct effect on ZIKV viral particles, plaque assay was performed on ZIKV incubated with AMPs. GF-17, BMAP-18, and RI-10 (10 µM) was individually mixed with ZIKV and incubated at 37°C for 1–4 h before plaque assay was performed (Figure ​(Figure7A).7A). These treatment time points were chosen based on a prior report on direct inactivation of vaccinia virions by LL-37 after 2-h incubation (38). After quantification of ZIKV plaques, we found that the effects of GF-17 to inhibit infectious ZIKV virions in the inoculum were both dose- and time-dependent. GF-17 inactivated Zika virions by >95% after 1-h incubation and the effect increased to >99% after 2-h incubation and 99% after 4-h incubation (Figure ​(Figure7B).7B). Direct incubation of GF-17 and ZIKV at 10 µM and 4 h caused the most virions reduction compared with those of lower doses and shorter time points. In contrast, direct incubation of BMAP-18 or RI-10 with ZIKV did not significantly change the number of infectious virions at all the time points (1, 2, 4 h). Therefore, these data demonstrate that the antiviral properties of GF-17 against ZIKV can be achieved via a direct interaction with and inactivation of ZIKV particles.

 

 

Figure 7

GF-17 directly inactivates Zika virions. (A) Experimental scheme. Briefly, Zika virus (ZIKV) virions were directly treated with antimicrobial peptides at 37°C. Part of the inoculum was removed at the indicated time points and serial diluted for the plaque-forming assay to determine the number of infectious Zika virions. (B) Quantification of the viral plaques was performed and plaque-forming unit at each of the treatment groups was shown. ANOVA and Bonferroni post-test were performed on all groups. *** p < 0.001, as compared with the ZIKV control group (CTL, control).

Go to:

Discussion

The ZIKV epidemic in South America in 2015 and 2016 is known to cause severe congenital central nervous system (CNS) malformations such as microcephaly, cerebral atrophy, ventriculomegaly, ocular anomalies, and visual/auditory impairments (39). ZIKV infection is also linked to adult GBS and incidence of laboratory confirmation of a ZIKV infection continues to increase among GBS cases (11, 40, 41). Although several therapeutic approaches have been suggested to be effective against ZIKV, including FDA-approved drugs, type-I IFNs, and live-attenuated vaccine (42–46), currently no vaccination or treatment is available for human use, especially for pregnant women and fetuses (47). In the present study, we demonstrated for the first time that AMPs derived from human and bovine cathelicidins have potent antiviral activity against ZIKV. Humans have only one cathelicidin, which is naturally cleaved to form LL-37. We have further identified that GF-17, which corresponds to the major antimicrobial region (residues 17–32) of LL-37 (28, 48), remains potent against ZIKV and has less cytotoxicity compared with LL-37. Inhibition of IFN signaling partially reversed GF-17-mediated viral inhibition. More importantly, direct incubation with GF-17 specifically reduced the number of infectious Zika virions. Therefore, cathelicidin-derived GF-17 potently inhibits ZIKV through direct inactivation as well as via the IFN pathway.

Antimicrobial peptides are able to stimulate antiviral effects through multiple mechanism of action. For example, AMPs with similar secondary structures may have diverging effects on viral replication (49–51). Furthermore, the same AMPs may exert antiviral activity on different viruses through distinct mechanisms (52, 53). Human AMP LL-37 was previously shown to have antiviral activity against HIV-1, influenza A virus, Respiratory Syncytial Virus, and Vaccinia Virus (38, 54–57). However, LL-37 is limited for therapeutic use because of its length of 37 residues, making it costly to chemically synthesize. In addition, pathogens have evolved to compromise the efficacy of LL-37. For instance, pandemic influenza A virus H1N1 2009 (Cal09) is known to resist to LL-37 but not a fragment of LL-37 (54). In the current study, we mainly focused on two cathelicidin-derived peptides: GF-17 and BMAP-18 because of their higher specificity to ZIKV. Our data demonstrate that both GF-17 and BMAP-18 have strong antiviral properties against ZIKV in vitro and the antiviral activities can be achieved at low micromolar concentrations. Bovine cathelicidins BMAP-18 was used to show the specificity and uniqueness of human cathelicidins. Our comparison of human and bovine cathelicidins reveals that human cathelicidin might have achieved an evolutional significance to protect humans from viral infection because it works by directly inactivating virus, whereas the bovine cathelicidin-derived peptide is unable to work.

Inhibition of IFN signaling pathway partially blocks the anti-ZIKV effect of BMAP-18 and GF-17. This is consistent with the data that suggest IFN signaling as an important factor regulating ZIKV susceptibility (58, 59). It is unclear how ZIKV continues to replicate despite the apparent induction of type-I IFN by AMPs in the astrocytes. ZIKV may use NS5, a non-structural protein of ZIKV, to antagonize host IFN response by preventing JAK-STAT signaling (60).

One possible mechanism of action by GF-17 is to damage pathogen membrane envelope and interrupt the viral membrane integrity, as previously reported as a carpet-based mechanism (38, 61). Analysis of the sequences of LL-37, GF-17, GI-20, and RI-10 together with their anti-ZIKV activity suggests that residues 1–12 and 33–37 of LL-37 are not essential for the anti-ZIKV effect. In contrast, residues 18 and 29–32 appear to be critical in that antiviral effect are lost if these residues are not present. In addition, residues 13–16 appear to be important in that antiviral effect are modestly weakened if these residues are removed. Analysis of the sequence of 17BIPHE2, Merecidin, and their antiviral activity also suggests that residue R23 is critical since its substitution significantly reduces the antiviral effect. This is consistent with our previous observation that substitution of lysines with arginines increased anti-HIV effects (62). Therefore, these data suggest that residues 17–32 of LL-37 are critical for the optimal anti-ZIKV activities of LL-37.

Few drug candidates are available to safely and effectively reduce viral load and prevent the development of disease after infection (42, 44, 45, 63–72). Compared with the reported drug candidates, AMPs have multiple advantages. First, treatment with GF-17 and BMAP-18 may be a safer choice compared with other drug candidates since the LL-37 is already present in the human body as a component of innate immune system. Second, the antiviral effect of AMPs is rapid, potent, and concentration-dependent. At 10 µM, the reduction of ZIKV RNA by GF-17 and BMAP-18 starts at 2-h post-peptide treatment and ZIKV RNA levels are reduced by over 99% and 95% at 48 h in astrocytes, respectively. Third, the AMPs are effective when applied either before or after ZIKV infection, which indicates the potential use of the peptides as an anti-ZIKV drug both prophylactically and therapeutically. An additional advantage of AMP is that they function through multiple mechanisms. In the event when IFN signaling is compromised by the virus, peptides are still expected to work against the virus via a direct inactivation mechanism. However, it is unclear whether GF-17 and BMAP-18 can cross placental and blood–brain barrier. Future studies are needed to evaluate the efficacy of GF-17 and BMAP-18 in vivo and how to deliver the peptides to the CNS.

Go to:

Conclusion

Cathelicidin-derived AMPs potently inhibit ZIKV infection in Vero cells and human fetal astrocytes. GF-17 mediates anti-ZIKV effect through both a direct inactivation of viral particle and partially through type-I IFN signaling, whereas BMAP-18 inhibits ZIKV through type-I IFN signaling. Strategies based on the peptides documented herein might be useful in halting ZIKV infection both prophylactically and therapeutically.

Go to:

Ethics Statement

All experiments for human fetal astrocyte generation were performed with the approval of the Scientific Research Oversight Committee at the University of Nebraska Medical Center (UNMC). Human fetal brain tissues were obtained from elective aborted specimens (gestational age 12 weeks to 16 weeks) following completion of the abortion procedure through collaborative works with the Birth Defects Research laboratory at University of Washington. The protocol is in compliance with all relevant state and federal regulations and is approved by the University of Washington Institutional Review Board (IRB, Protocol no. 96-1826-A07) and UNMC IRB (Protocol no. 123-02-FB). Written informed consent was obtained with all subjects using an IRB-approved consent form at the University of Washington. All consenting subjects were donors of fetal tissue that were 19 years of age or older with clear comprehension. The UNMC investigators do not have access to signed consent forms.

Go to:

Author Contributions

MH, YH, GW, and JZ conceived and designed the experiments. MH, HZ, YL, and JZ performed the experiments. MH, HZ, YH, GW, JHZ, and JZ analyzed the data. GW and BT contributed reagents/materials/analysis tools. MH, YH, GW, and JZ wrote the paper. All authors read and approved the final manuscript.

Go to:

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Go to:

Acknowledgments

We thank Drs. Santhi Gorantla, Zenghan Tong, Justin Peer, Runze Zhao, and Li Wu for the technical support of this work. Julie Ditter, Lenal Bottoms, Myhanh Che, Johna Belling, and Robin Taylor provided outstanding administrative and secretarial support.

Go to:

Footnotes

Funding. This work was supported by grants from National Key Basic Research Program of China (973Program Grant No. 2014CB965000, project 1 No. 2014CB965001, and project 3No. 2014CB965003 to JZ); National Key Plan for Scientific Research and development of China (2016YFC1306000 to BT); National Natural Science Foundation of China (81430023 to BT); Innovative Research Groups of the National Natural Science Foundation of China (#81221001 to JZ); Joint Research Fund for Overseas Chinese, Hong Kong and Macao Young Scientists of the National Natural Science Foundation of China (#81329002 to JZ); and National Institutes of Health: R01 AI105147 (to GW), 2R56NS041858-15A1 (to JZ), 1R01NS097195-01 (to JZ), and R03 NS094071-01 (to YH).

Go to:

Supplementary Material

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00722/full#supplementary-material.

Click here for additional data file.^{(4.8M, docx)}

Go to:

References

1. Faye O, Freire CC, Iamarino A, Faye O, De Oliveira JV, Diallo M, et al. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl Trop Dis (2014) 8:e2636.10.1371/journal.pntd.0002636 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Boeuf P, Drummer HE, Richards JS, Scoullar MJ, Beeson JG. The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact. BMC Med (2016) 14:112.10.1186/s12916-016-0660-0 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet (2016) 387:2125–32.10.1016/S0140-6736(16)00651-6 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Costello A, Dua T, Duran P, Gulmezoglu M, Oladapo OT, Perea W, et al. Defining the syndrome associated with congenital Zika virus infection. Bull World Health Organ (2016) 94:406–406A.10.2471/BLT.16.176990 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med (2016) 374:951–8.10.1056/NEJMoa1600651 [PubMed] [CrossRef] [Google Scholar]
6. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects – reviewing the evidence for causality. N Engl J Med (2016) 374:1981–7.10.1056/NEJMsr1604338 [PubMed] [CrossRef] [Google Scholar]
7. World Health Organization. Zika Virus Country Classification Scheme: Interim Guidance. Geneva: World Health Organization; (2017). [Google Scholar]
8. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, et al. Zika virus infection complicated by Guillain-Barre syndrome – case report, French Polynesia, December 2013. Euro Surveill (2014) 19(9):20720.10.2807/1560-7917.ES2014.19.9.20720 [PubMed] [CrossRef] [Google Scholar]
9. Brasil P, Sequeira PC, Freitas AD, Zogbi HE, Calvet GA, De Souza RV, et al. Guillain-Barre syndrome associated with Zika virus infection. Lancet (2016) 387:1482.10.1016/S0140-6736(16)30058-7 [PubMed] [CrossRef] [Google Scholar]
10. Calvet GA, Santos FB, Sequeira PC. Zika virus infection: epidemiology, clinical manifestations and diagnosis. Curr Opin Infect Dis (2016) 29:459–66.10.1097/QCO.0000000000000301 [PubMed] [CrossRef] [Google Scholar]
11. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (2016) 387:1531–9.10.1016/S0140-6736(16)00562-6 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. Pan American Health Organization/World Health Organization. Epidemiological Update: Neurological Syndrome, Congenital Anomalies and Zika Virus Infection. Washington, DC: PAHO/WHO; (2016). [Google Scholar]
13. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature (2002) 415:389–95.10.1038/415389a [PubMed] [CrossRef] [Google Scholar]
14. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents (2004) 24:536–47.10.1016/j.ijantimicag.2004.09.005 [PubMed] [CrossRef] [Google Scholar]
15. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res (2016) 44:D1087–93.10.1093/nar/gkv1278 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Baxter AA, Lay FT, Poon IKH, Kvansakul M, Hulett MD. Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects. Cell Mol Life Sci (2017) 74:3809–25.10.1007/s00018-017-2604-z [PubMed] [CrossRef] [Google Scholar]
17. Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel) (2014) 7:545–94.10.3390/ph7050545 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Zanetti M, Gennaro R, Romeo D. The cathelicidin family of antimicrobial peptide precursors: a component of the oxygen-independent defense mechanisms of neutrophils. Ann N Y Acad Sci (1997) 832:147–62.10.1111/j.1749-6632.1997.tb46244.x [PubMed] [CrossRef] [Google Scholar]
19. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem (1996) 238:325–32.10.1111/j.1432-1033.1996.0325z.x [PubMed] [CrossRef] [Google Scholar]
20. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J Leukoc Biol (2005) 77:451–9.10.1189/jlb.0704380 [PubMed] [CrossRef] [Google Scholar]
21. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta (2006) 1758:1408–25.10.1016/j.bbamem.2006.03.030 [PubMed] [CrossRef] [Google Scholar]
22. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol (2009) 16:41–7.10.1097/MOH.0b013e32831ac517 [PubMed] [CrossRef] [Google Scholar]
23. Bucki R, Leszczynska K, Namiot A, Sokolowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp (Warsz) (2010) 58:15–25.10.1007/s00005-009-0057-2 [PubMed] [CrossRef] [Google Scholar]
24. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol (2012) 280:22–35.10.1016/j.cellimm.2012.11.009 [PubMed] [CrossRef] [Google Scholar]
25. Zheng J, Thylin MR, Ghorpade A, Xiong H, Persidsky Y, Cotter R, et al. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuroimmunol (1999) 98:185–200.10.1016/S0165-5728(99)00049-1 [PubMed] [CrossRef] [Google Scholar]
26. Ghorpade A, Holter S, Borgmann K, Persidsky R, Wu L. HIV-1 and IL-1 beta regulate Fas ligand expression in human astrocytes through the NF-kappa B pathway. J Neuroimmunol (2003) 141:141–9.10.1016/S0165-5728(03)00222-4 [PubMed] [CrossRef] [Google Scholar]
27. Huang Y, Li Y, Zhang H, Zhao R, Jing R, Xu Y, et al. Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869. Cell Discov (2018) 4:1–16.10.1038/s41421-018-0017-2 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Li X, Li Y, Han H, Miller DW, Wang G. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc (2006) 128:5776–85.10.1021/ja0584875 [PubMed] [CrossRef] [Google Scholar]
29. Wang G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem (2008) 283:32637–43.10.1074/jbc.M805533200 [PubMed] [CrossRef] [Google Scholar]
30. Menousek J, Mishra B, Hanke ML, Heim CE, Kielian T, Wang G. Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureusUSA300. Int J Antimicrob Agents (2012) 39:402–6.10.1016/j.ijantimicag.2012.02.003 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Wang X, Mishra B, Lushinikova T, Narayana JL, Wang G. Amino acid composition determines peptide activity spectrum and hot spot-based design of merecidin. Adv Biosyst (2018) 2:1700259. [Google Scholar]
32. Wang G, Watson KM, Buckheit RW, Jr. Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother (2008) 52:3438–40.10.1128/AAC.00452-08 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Wang G, Hanke ML, Mishra B, Lushnikova T, Heim CE, Chittezham Thomas V, et al. Transformation of human cathelicidin LL-37 into selective, stable, and potent antimicrobial compounds. ACS Chem Biol (2014) 9:1997–2002.10.1021/cb500475y [PMC free article] [PubMed] [CrossRef] [Google Scholar]
34. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem (1996) 271:28375–81.10.1074/jbc.271.45.28375 [PubMed] [CrossRef] [Google Scholar]
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 25:402–8.10.1006/meth.2001.1262 [PubMed] [CrossRef] [Google Scholar]
36. Liu S, Delalio LJ, Isakson BE, Wang TT. AXL-mediated productive infection of human endothelial cells by Zika virus. Circ Res (2016) 119:1183–9.10.1161/CIRCRESAHA.116.309866 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
37. Huang Y, Walstrom A, Zhang L, Zhao Y, Cui M, Ye L, et al. Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages. PLoS One (2009) 4:e5397.10.1371/journal.pone.0005397 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol (2004) 172:1763–7.10.4049/jimmunol.172.3.1763 [PubMed] [CrossRef] [Google Scholar]
39. Vouga M, Baud D. Imaging of congenital Zika virus infection: the route to identification of prognostic factors. Prenat Diagn (2016) 36:799–811.10.1002/pd.4880 [PubMed] [CrossRef] [Google Scholar]
40. Dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, De Oliveira WK, et al. Zika virus and the Guillain-Barre syndrome – case series from seven countries. N Engl J Med (2016) 375:1598–601.10.1056/NEJMc1609015 [PubMed] [CrossRef] [Google Scholar]
41. Parra B, Lizarazo J, Jimenez-Arango JA, Zea-Vera AF, Gonzalez-Manrique G, Vargas J, et al. Guillain-Barre syndrome associated with Zika virus infection in Colombia. N Engl J Med (2016) 375:1513–23.10.1056/NEJMoa1605564 [PubMed] [CrossRef] [Google Scholar]
42. Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe (2016) 20:259–70.10.1016/j.chom.2016.07.004 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S, et al. The IFITMs inhibit Zika virus replication. Cell Rep (2016) 15:2323–30.10.1016/j.celrep.2016.05.074 [PubMed] [CrossRef] [Google Scholar]
44. Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med (2016) 22:1101–7.10.1038/nm.4184 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
45. Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, et al. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res (2017) 137:134–40.10.1016/j.antiviral.2016.11.023 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
46. Shan C, Muruato AE, Nunes BTD, Luo H, Xie X, Medeiros DBA, et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med (2017) 23:763–7.10.1038/nm.4322 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
47. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. Lancet (2017) 390:2099–109.10.1016/S0140-6736(17)31450-2 [PubMed] [CrossRef] [Google Scholar]
48. Wang G, Epand RF, Mishra B, Lushnikova T, Thomas VC, Bayles KW, et al. Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL-37. Antimicrob Agents Chemother (2012) 56:845–56.10.1128/AAC.05637-11 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Yasin B, Pang M, Turner JS, Cho Y, Dinh NN, Waring AJ, et al. Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides. Eur J Clin Microbiol Infect Dis (2000) 19:187–94.10.1007/s100960050457 [PubMed] [CrossRef] [Google Scholar]
50. Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M. In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs. Peptides (2003) 24:1723–31.10.1016/j.peptides.2003.07.025 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
51. Albiol Matanic VC, Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents (2004) 23:382–9.10.1016/j.ijantimicag.2003.07.022 [PubMed] [CrossRef] [Google Scholar]
52. Belaid A, Aouni M, Khelifa R, Trabelsi A, Jemmali M, Hani K. In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. J Med Virol (2002) 66:229–34.10.1002/jmv.2134 [PubMed] [CrossRef] [Google Scholar]
53. Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, et al. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology (2005) 334:264–75.10.1016/j.virol.2005.02.002 [PubMed] [CrossRef] [Google Scholar]
54. Tripathi S, Wang G, White M, Qi L, Taubenberger J, Hartshorn KL. Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses. PloS One (2015) 10:e0124706.10.1371/journal.pone.0124706 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One (2011) 6:e25333.10.1371/journal.pone.0025333 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
56. Currie SM, Findlay EG, Mchugh BJ, Mackellar A, Man T, Macmillan D, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One (2013) 8:e73659.10.1371/journal.pone.0073659 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
57. Hou M, Zhang N, Yang J, Meng X, Yang R, Li J, et al. Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo. Cell Physiol Biochem (2013) 32:614–23.10.1159/000354465 [PubMed] [CrossRef] [Google Scholar]
58. Chan JF, Zhang AJ, Chan CC, Yip CC, Mak WW, Zhu H, et al. Zika virus infection in dexamethasone-immunosuppressed mice demonstrating disseminated infection with multi-organ involvement including orchitis effectively treated by recombinant type I interferons. EBioMedicine (2016) 14:112–22.10.1016/j.ebiom.2016.11.017 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
59. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe (2016) 19:720–30.10.1016/j.chom.2016.03.010 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
60. Best SM. The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling. J Virol (2017) 91:e01970–16.10.1128/JVI.01970-16 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
61. Gazit E, Miller IR, Biggin PC, Sansom MS, Shai Y. Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes. J Mol Biol (1996) 258:860–70.10.1016/j.peptides.2010.07.028 [PubMed] [CrossRef] [Google Scholar]
62. Wang G, Watson KM, Peterkofsky A, Buckheit RW, Jr. Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. Antimicrob Agents Chemother (2010) 54:1343–6.10.1128/AAC.01448-09 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (2016) 353:1129–32.10.1126/science.aah6157 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
64. Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, Demaso CR, et al. Rapid development of a DNA vaccine for Zika virus. Science (2016) 354:237–40.10.1126/science.aai9137 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
65. Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, et al. Vaccine protection against Zika virus from Brazil. Nature (2016) 536:474–8.10.1038/nature18952 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
66. Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. The viral polymerase inhibitor 7-deaza-2’-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis (2016) 10:e0004695.10.1371/journal.pntd.0004695 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
67. Adcock RS, Chu YK, Golden JE, Chung DH. Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay. Antiviral Res (2017) 138:47–56.10.1016/j.antiviral.2016.11.018 [PubMed] [CrossRef] [Google Scholar]
68. Balasubramanian A, Teramoto T, Kulkarni AA, Bhattacharjee AK, Padmanabhan R. Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antiviral Res (2017) 137:141–50.10.1016/j.antiviral.2016.11.015 [PubMed] [CrossRef] [Google Scholar]
69. Barouch DH, Thomas SJ, Michael NL. Prospects for a Zika virus vaccine. Immunity (2017) 46:176–82.10.1016/j.immuni.2017.02.005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
70. Griffin BD, Muthumani K, Warner BM, Majer A, Hagan M, Audet J, et al. DNA vaccination protects mice against Zika virus-induced damage to the testes. Nat Commun (2017) 8:15743.10.1038/ncomms15743 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Lee H, Ren J, Nocadello S, Rice AJ, Ojeda I, Light S, et al. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Res (2017) 139:49–58.10.1016/j.antiviral.2016.12.016 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
72. Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol (2017) 1499:109–21.10.1007/978-1-4939-6481-9_6 [PubMed] [CrossRef] [Google Scholar]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA